Business Description

Laboratory Corp of America Holdings
NAICS : 621511
SIC : 8071
Description
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.07 | |||||
Equity-to-Asset | 0.51 | |||||
Debt-to-Equity | 0.62 | |||||
Debt-to-EBITDA | 2.05 | |||||
Interest Coverage | 14.37 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 3.44 | |||||
Beneish M-Score | -2.4 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 14.4 | |||||
3-Year EBITDA Growth Rate | 27.7 | |||||
3-Year EPS without NRI Growth Rate | 41.5 | |||||
3-Year FCF Growth Rate | 44.4 | |||||
3-Year Book Growth Rate | 16.1 | |||||
Future 3-5Y EPS without NRI Growth Rate | -2.03 | |||||
Future 3-5Y Total Revenue Growth Rate | 2.19 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 100 | |||||
9-Day RSI | 98.89 | |||||
14-Day RSI | 91.23 | |||||
6-1 Month Momentum % | -4.81 | |||||
12-1 Month Momentum % | -23.98 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.73 | |||||
Quick Ratio | 1.55 | |||||
Cash Ratio | 0.16 | |||||
Days Inventory | 15.04 | |||||
Days Sales Outstanding | 53.66 | |||||
Days Payable | 23.95 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 0.93 | |||||
Dividend Payout Ratio | 0.08 | |||||
Forward Dividend Yield % | 1.19 | |||||
5-Year Yield-on-Cost % | 0.93 | |||||
3-Year Average Share Buyback Ratio | 2 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 31.39 | |||||
Operating Margin % | 16.35 | |||||
Net Margin % | 11.51 | |||||
ROE % | 16.88 | |||||
ROA % | 8.59 | |||||
ROIC % | 11.33 | |||||
ROC (Joel Greenblatt) % | 68.67 | |||||
ROCE % | 13.51 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 13.37 | |||||
Forward PE Ratio | 14 | |||||
PE Ratio without NRI | 13.56 | |||||
Shiller PE Ratio | 20.65 | |||||
Price-to-Owner-Earnings | 18.61 | |||||
PEG Ratio | 0.71 | |||||
PS Ratio | 1.54 | |||||
PB Ratio | 2.23 | |||||
Price-to-Free-Cash-Flow | 15.83 | |||||
Price-to-Operating-Cash-Flow | 11.75 | |||||
EV-to-EBIT | 11.7 | |||||
EV-to-Forward-EBIT | 12.49 | |||||
EV-to-EBITDA | 9.16 | |||||
EV-to-Forward-EBITDA | 10.69 | |||||
EV-to-Revenue | 1.84 | |||||
EV-to-Forward-Revenue | 1.88 | |||||
EV-to-FCF | 19.11 | |||||
Price-to-Projected-FCF | 0.9 | |||||
Price-to-DCF (Earnings Based) | 0.53 | |||||
Price-to-DCF (FCF Based) | 0.68 | |||||
Price-to-Median-PS-Value | 0.99 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.61 | |||||
Earnings Yield (Greenblatt) % | 8.55 | |||||
Forward Rate of Return (Yacktman) % | 26.18 |